NasdaqGS:ILMNLife Sciences
Illumina (ILMN) Stock Climbs On Clinical Growth Despite Margin Pressure
Illumina walked into this earnings print with the stock essentially flat on the day, trading near US$205 after a strong 90 day run. The market did not stampede in either direction; however, the quarter itself was anything but quiet. Revenue landed at about US$1.16b and non GAAP earnings per share reached roughly US$1.31, both tied closely to clinical sequencing strength and NovaSeq X adoption.
For a company often viewed as a long term genomics platform story, the real headline this time is...